research Local heroes or villains: tissue-resident memory T cells in human health and disease
Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.
Search
for
Sort by
Research
840-870 / 1000+ results research TERMIS ‐ AMERICAS Toronto, Ontario, Canada July 10–13, 2022
Advancements in skin treatment and wound healing include promising gene therapy, 3D skin models, and potential new therapies.
research Cytokine-targeted treatment in alopecia areata - new possibilities?
New cytokine-targeted therapies show promise for treating alopecia areata.
research Dissecting Cellulitis of the Scalp: Linking Pathogenesis to Therapy
New treatments like biologics and JAK inhibitors show promise for severe scalp inflammation when traditional methods fail.
research 470 Exploring the possible involvement of skin-resident memory T cells in refractory chronic alopecia areata
Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.
research Emerging Therapies for Acne Vulgaris
New acne treatments show promise as alternatives to traditional therapies.
research MODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW
JAK inhibitors show promise for treating alopecia areata, but more research is needed.
research 001 Human scalp hair follicles are protected from alopecia areata in vivo by regulatory γδT cells
γδT cells can protect hair follicles from alopecia areata and promote hair regrowth.
research Read-Through for Nonsense Mutations in Type XVII Collagen‒Deficient Junctional Epidermolysis Bullosa
A new therapy for a skin blistering condition has not been developed yet.
research Treatment of alopecia areata: “What is new on the horizon?”
New treatments for alopecia areata may target specific immune cells and pathways involved in hair loss.
research Platelet-Rich Plasma Therapy for Telogen Effluvium: A Comprehensive Evaluation of Efficacy and Safety
Combining PRP with Tressfix Serum is more effective for hair regrowth in telogen effluvium than using either alone.
research Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment—A Single Center Case Series
Individualized treatments may help manage Dercum's disease symptoms.
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
research Alopecia areata mit gutem Ansprechen auf Tofacitinib
Tofacitinib helped regrow hair in a woman with alopecia areata.
research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.
research Topical immunotherapies
Some treatments that modify the immune system might help with certain types of hair loss but haven't been explored for common hair loss alone.
research Emerging pharmacotherapies for Androgenetic Alopecia
New treatments for hair loss focus on targeting specific causes to improve effectiveness and safety.
research Supplementary Material for: Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study
RCS-01 cell therapy is safe and improves skin gene expression.
research Local infusion of infliximab for the treatment of acute joint inflammation
Co-trimoxazole may help treat autoimmune diseases.
research An overview of the more significant therapeutic effects of TECAR therapy
TECAR therapy helps with pain relief, reduces inflammation, relaxes muscles, heals tissues, and is safe and effective for many conditions.
research Alopecia areata and ritlecitinib: Unravelling response trajectories
Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
research Topical therapy and skin care for transplant‐associated atopic dermatitis in children and adolescents
Topical treatments and skin care improve transplant-related atopic dermatitis in children.
research Sustaining treatment response in alopecia areata through tofacitinib dose tapering: A single-center retrospective study
research LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome
Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
research Overcoming hurdles: Side effects with old drugs and achieving success with novel drug in alopecia areata
Tofacitinib effectively regrew scalp hair in an 11-year-old girl with alopecia areata.
research Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
research Topical RT1640 treatment effectively reverses gray hair and stem cell loss in a mouse model of radiation‐induced canities
RT1640 treatment reverses gray hair and promotes hair growth in mice.
research Group Treatment for Trichotillomania: Behavior Therapy Versus Supportive Therapy
Group behavior therapy reduces hair-pulling symptoms more than supportive therapy but has limited long-term effectiveness.